grey market retatrutide forum the weight loss drug everyone is asking about isn't FDA approved yet. retatrutide. triple agonist. GLP-1 + GIP + glucagon. phase 3 data showing ~29% body weight reduction. people are already sourcing Retatrutide, an experimental weight-loss drug,

Beyond that, some other potential risks included sleep issues, low blood pressure (sometimes leading to fainting), kidney stones, arthritis, and acute pancreatitis

The semaglutide component drives the primary weight loss effect

For employers who cover these medications, the budgetary impact is real and growing

A vague sense of feeling satisfied with smaller portions

In the STEP 1 trial, participants receiving semaglutide 2.4 mg weekly experienced significant reductions in triglycerides (mean decrease of 15-20%) and total cholesterol compared with placebo

Side effects are common: about 43% of people felt nauseous, 33% had diarrhea, and about 1 in 5 experienced tingling or burning skin sensations (called dysesthesia) at the highest dose